Safety and Efficacy of GSK2248761, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Treatment-Naive HIV-1-Infected Subjects
Antimicrobial Agents and Chemotherapy, 04/26/2012
Zala C et al. – No nonnucleoside reverse transcriptase inhibitor (NNRTI)resistance mutations emerged during the study. GSK2248761 at 100 to 800 mg QD for 7 days was well tolerated, demonstrated potent antiviral activity in treatment–naive HIV–infected subjects, and had favorable PK and resistance profiles. GSK2248761 is no longer in clinical development.